Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).

Brown S, Tadros AB, Montagna G, Bell T, Crowley F, Gallagher EJ, Dayan JH.

Open source

DOI: 10.3389/fphar.2024.1457363
Published: 2024-09-04
Container: Front Pharmacol
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2024.1457363,
  title = {Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).},
  author = {Brown S and  Tadros AB and  Montagna G and  Bell T and  Crowley F and  Gallagher EJ and  Dayan JH.},
  year = {2024},
  journal = {Front Pharmacol},
  doi = {10.3389/fphar.2024.1457363},
  url = {https://doi.org/10.3389/fphar.2024.1457363}
}

RIS

TY  - JOUR
TI  - Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).
AU  - Brown S
AU  -  Tadros AB
AU  -  Montagna G
AU  -  Bell T
AU  -  Crowley F
AU  -  Gallagher EJ
AU  -  Dayan JH.
PY  - 2024
JO  - Front Pharmacol
DO  - 10.3389/fphar.2024.1457363
UR  - https://doi.org/10.3389/fphar.2024.1457363
ER  -

APA

S, B., AB, T., G, M., T, B., F, C., EJ, G., & JH., D. (2024). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).. Front Pharmacol. https://doi.org/10.3389/fphar.2024.1457363

Source records

europe-pmc · retrieved 2026-09-27T03:45:20.333Z
doaj · retrieved 2026-09-27T03:45:20.347Z